IMVTImmunovant, Inc.
$30.48+106% 1Y
$30.48
$14.9052 weeks$45.00
IMVT in its own filings
Nothing in IMVT's filing record raises a hard flag: no restatement, late filing, bankruptcy or delisting notice, and no auditor change next to one. That is the common case, not a distinction.
157
Events found in the filings · across 643 filings · the record starts in 2019
- Hard flags
- none
Hard flags
- Most recent filing
- Sep 3, 2026
Most recent filing · Form 8-K
- Record starts
- Feb 11, 2019
Record starts · the earliest filing Ryufin holds for this name
Details›
- Next results filingsame week as a year ago
- expected around Nov 9, 2026
- Change in certifying accountanthistorical
- 2019-12-20
- Security removed from listing or deregisteredhistorical · usually a matured note or preferred class, not the common shares
- 2020-06-15
- SEC comment-letter activity25 occurrences
- 2024-02-28
SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 6, 2026Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2026.Earnings release · press release
- May 20, 2026Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026.Earnings release · press release
- Feb 6, 2026Immunovant Provides Corporate Updates and Reports Financial Results for the Third Quarter Ended December 31, 2025.Earnings release · press release
- Dec 12, 2025On December 10, 2025, Immunovant, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Leerink Partners LLC (“Leerink Partners”), relating to the issuance and sale in an underwritten offering by the Company of 26.2 million shares (the “Shares”) of the Company’s common stock …Other event · Form 8-K
- Dec 11, 2025Outlook On December 10, 2025, Immunovant, Inc. (the “Company”) announced the pricing of an underwritten offering of its common stock, with anticipated gross proceeds to the Company of approximately $550 million, before deducting underwriting discounts and commissions and other expenses payable by the Company in …Other event · Form 8-K
- Nov 21, 2025Michael Geffner, M.D., M.B.A., ceased serving as the Chief Medical Officer of Immunovant, Inc. (the “Company”), effective November 21, 2025 (“Separation Date”), in connection with the Company’s restructuring of its R&D leadership structure under the Company’s Chief Executive Officer, Eric Venker, M.D., PharmD. The …Director or officer change · Form 8-K
- Nov 10, 2025Immunovant Provides Corporate Updates and Reports Financial Results for the Second Quarter Ended September 30, 2025.Earnings release · press release
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
opening the record…